Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × famitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 7 Breast Neoplasms 6 Carcinoma, Non-Small-Cell Lung 3 Uterine Cervical Neoplasms 2 Solid Tumor 2 Small Cell Lung Carcinoma 2 Ovarian Neoplasms 2 Nasopharyngeal Carcinoma 2 Melanoma 2 Colorectal Neoplasms 2 Cervical Cancer Metastatic 2 Carcinoma, Renal Cell 2 Thyroid Neoplasms 1 Recurrence 1 Non-squamous Non-small-cell Lung Cancer 1 Non Squamous Non Small Cell Lung 1 Neoplasms 1 Neoplasm Metastasis 1 Neoadjuvant Therapy 1 NSCLC 1 Gastrointestinal Stromal Tumors 1 Gastro-enteropancreatic neuroendocrine tumor 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 Disease Progression 1 Cholangiocarcinoma 1 Carcinoma, Transitional Cell 1 BRCA-Mutated Breast Carcinoma 1 Advanced Solid Tumor 1 Advanced NSCLC 1

Interventions

Pemetrexed 14 Carboplatin 12 osimertinib 11 Drug Therapy 9 aflutinib 8 Gefitinib 8 Radiotherapy 6 Docetaxel 6 Cisplatin 6 pembrolizumab 5 anlotinib 5 Radiosurgery 5 icotinib 4 Vinorelbine 4 Paclitaxel 4 Gemcitabine 4 Erlotinib Hydrochloride 4 tislelizumab 3 camrelizumab 3 apatinib 3 HM781-36B 3 toripalimab 2 spartalizumab 2 rezivertinib 2 dacomitinib 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05005468 2021-08-13

CAMFA-L

Shanghai Chest Hospital

Phase 2 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡